Vinegar as a Screening Tool in the U.S.
Sandra Swain, MD, medical director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses the utility for vinegar as a screening tool in the U.S.
Sandra Swain, MD, medical director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses the utility for vinegar as a screening tool in the U.S.
In a cluster-randomized study that analyzed 150,000 women in Mumbai, India, vinegar (acetic acid) demonstrated to be an adequate screening tool for cervical cancer.
Swain believes that the use of vinegar as a screening tool has a greater implication in developing countries with no resources and probably will not be adopted in the U.S.
Clinical Pearls
A recent study found that a DNA test was superior to vinegar, though screening was only done once. In the Mumbai study, screening was done four times every two years. The idea of an inexpensive DNA test is being examined, Swain says.
- Swain says vinegar has little utility as a screening tool for cervical cancer in the U.S.
- Research is being conducted looking at an inexpensive DNA test
- The Mumbai study has more implication for developing countries
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Novel Therapies and Combinations Lead the Way in Women’s Cancers in 2024
January 3rd 2025Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 blockade, or the use of fam-trastuzumab deruxtecan-nxki in endometrial cancer.
Read More
